Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

BACKGROUND: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)....

Descripción completa

Detalles Bibliográficos
Autores principales: Elliott, Perry, Drachman, Brian M., Gottlieb, Stephen S., Hoffman, James E., Hummel, Scott L., Lenihan, Daniel J., Ebede, Ben, Gundapaneni, Balarama, Li, Benjamin, Sultan, Marla B., Shah, Sanjiv J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763250/
https://www.ncbi.nlm.nih.gov/pubmed/34923848
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.008193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763250/
https://www.ncbi.nlm.nih.gov/pubmed/34923848
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.008193

Ejemplares similares